Avapritinib Improved Skin Findings In Patients With Indolent Systemic Mastocytosis (ISM) In the Registrational, Double-Blind, Placebo Controlled PIONEER Study

ISM, characterized by mast cell (MC) accumulation driven by D816V-mutant KIT, can be associated with debilitating symptoms including skin lesions. Skin findings, including MC burden and immunophenotype, were characterized in patients with ISM treated with avapritinib, a selective KIT D816V inhibitor, vs placebo in PIONEER Part 2 (NCT03731260).